MindBio Therapeutics Expands AI Voice Platform with Fatigue Detection for Workplace Safety
MindBio Therapeutics is broadening its AI voice analytics platform to include fatigue detection alongside drug and alcohol impairment screening, targeting high-risk industries like mining and aviation.
MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) is expanding its AI-driven voice analytics platform to include fatigue detection, aiming to enhance safety in high-risk workplace environments. The company announced on May 11 that it has developed a fatigue recognition system using speech analytics and proprietary artificial intelligence models, according to a news release (https://ibn.fm/4KNzG).
The fatigue prediction module will be added to MindBio’s planned Edge AI Intoxication Detection Kiosks, which are designed for industrial workplaces. This expansion complements the company’s existing drug and alcohol impairment screening capabilities, creating a comprehensive non-invasive testing solution. MindBio has filed a patent application covering detection of neurologically active substances and fatigue through voice analysis.
The move positions MindBio as a potential alternative to traditional testing methods such as breath, saliva, blood, and laboratory-based systems. The company is initially targeting sectors including mining, aviation, transportation, and construction—industries where fatigue and impairment pose significant safety risks. Management stated that commercial testing of the kiosk hardware and software remains on track for late Q2 2026.
This development is significant because fatigue is a major contributor to workplace accidents, particularly in safety-sensitive industries. By offering a non-invasive, real-time detection method through voice analysis, MindBio’s technology could help employers identify impaired or fatigued workers before accidents occur. The integration of fatigue detection into the same platform as intoxication screening provides a more holistic approach to workplace safety, potentially reducing reliance on multiple separate testing systems.
The announcement also underscores the growing role of artificial intelligence in occupational health and safety. As companies seek to minimize risks and comply with regulations, AI-driven voice analysis offers a scalable and efficient solution. For MindBio, this expansion could open new market opportunities beyond its initial focus on drug and alcohol detection, broadening its commercial appeal.
Investors and industry stakeholders will be watching the late Q2 2026 timeline for commercial testing, as successful deployment could lead to widespread adoption in high-risk workplaces. The company’s patent application further solidifies its intellectual property position in the emerging field of voice-based impairment detection.